- Home
- MLSS vs MRSN Comparison
MLSS vs MRSN Comparison
Compare MLSS & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLSS | MRSN |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 138.8M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MLSS | MRSN |
|---|---|---|
| Price | $0.36 | $27.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.00 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 3.2M | 237.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,929,517.00 | ★ $33,180,000.00 |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $7.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.59 | N/A |
| 52 Week Low | $0.28 | $5.21 |
| 52 Week High | $1.39 | $70.73 |
Technical Indicators
Market Signals| Indicator | MLSS | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 83.68 |
| Support Level | $0.31 | $27.31 |
| Resistance Level | $0.32 | $28.36 |
| Average True Range (ATR) | 0.03 | 0.52 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 85.05 | 51.65 |
Price Performance
Historical ComparisonAbout MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.